Method for the treatment of inflammation
View Patent ↗The present invention relates to a mycobacterial deoxyribonucleic acid (B-DNA) preserved and complexed on the mycobacterial cell wall (BCC) and a pharmaceutically acceptable carrier, wherein the BCC is effective in treating an inflammation in an animal having an inflammation. More particularly, the present invention relates to a Mycobacterium phlei deoxyribonucleic acid (M-DNA) preserved and complexed on Mycobacterium phlei cell wall (MCC) and a pharmaceutically acceptable carrier, wherein the MCC is effective in treating an inflammation in an animal having an inflammation.
1. A method for reducing inflammation in an animal having inflammation, comprising administering to the animal an effective amount of a composition comprising:
(a) a mycobacterial deoxyribonucleic acid obtained from a disrupted mycobacterium, wherein the mycobacterial deoxyribonucleic acid is preserved and complexed on a mycobacterial cell wall (BCC); and
(b) a pharmaceutically acceptable carrier, wherein the amount is effective to treat the inflammation.
2. The method of claim 1 , wherein the effective amount is effective to induce the synthesis of cytokine IL-10.
3. The method of claim 1 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.
4. A method for reducing inflammation in an animal having inflammation, comprising administering to the animal an effective amount of a composition comprising Mycobacterium phlei -DNA preserved and complexed on a Mycobacterium phlei cell wall (MCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to reduce the inflammation.
5. The method of claim 4 , wherein the effective amount is effective to induce the synthesis of cytokine IL-10.
6. The method of claim 4 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.
7. The method of claim 1 , wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from Mycobacterium phlei.
8. The method of claim 1 , wherein the animal has immune-mediated inflammation, osteoarthritis, rheumatoid arthritis, glomerulonephritis, colitis or cystitis.
9. The method of claim 1 , wherein the animal has osteoarthritis.
10. The method of claim 1 , wherein the animal has colitis.
11. The method of claim 1 , wherein the Mycobacterium is selected from the group consisting of M. vaccae, M. chelonei, M. smegmatis, M. terrae, M. duvalii, M. tuberculosis, M. bovis BCG, M. avium, M. Szulgai, M. scrofulaceum, M. xenopi, M. kansaii, M. gastr, M. fortuitious , or M. asiaticum.
12. The method of claim 4 , wherein the animal has immune-mediated inflammation, osteoarthritis, rheumatoid arthritis, glomerulonephritis, colitis, or cystitis.
13. The method of claim 4 , wherein the animal has osteoarthritis.
14. The method of claim 4 , wherein the animal has colitis.
15. A method for inducing IL-10 production in an animal comprising administering to the animal an effective amount of a composition comprising:
(a) a mycobacterial deoxyribonucleic acid obtained from a disrupted Mycobacterium , the mycobacterial deoxyribonucleic acid preserved and complexed on a mycobacterial cell wall (BCC); and
(b) a pharmaceutically acceptable carrier, wherein the amount is effective to induce IL-10 production.
16. The method of claim 15 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.
17. The method of claim 15 , wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from Mycobacierium phlei.
18. The method of claim 15 , wherein the Mycobacterium is selected from the group consisting of M. vaccae, M. chelonei, M. smegmatis, M. terrae, M. duvalii, M. tuberculosis, M. bovis BCG, M. avium, M. Szulgai, M. scrofulaceum, M. xenopi, M. kansaii, M. gastr, M. fortuitious , or M. asiaticum.
19. A method for inducing IL-10 production in an animal, comprising administering to the animal an effective amount of a composition comprising Mycobacterium phlei -DNA preserved and complexed on a Mycobacterium phlei cell wall (MCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to induce IL-10 production.
20. The method of claim 19 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.
21. The method of claim 19 , wherein the animal has immune-mediated inflammation, osteoarthritis, rheumatoid arthritis, glomerulonephritis, colitis, and cystitis.